Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701616 | 0.86 | KDR (0.41) | KDREPHX1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL2702150 | 0.86 | AR (0.39) | KDREPHX1SMN1; SMN2NPSR1PDK1 | |
| SCHEMBL2703380 | 0.84 | F2R (0.41) | KDRSMN1; SMN2NPSR1PDK1AR | |
| SCHEMBL2702110 | 0.83 | TDP1 (0.51) | TDP1POLBL3MBTL1RXFP1RECQL | |
| SCHEMBL9269418 | 0.80 | TDP1 (0.49) | TDP1POLBL3MBTL1RXFP1RECQL | |
| SCHEMBL202023 | 0.79 | KDR (0.68) | KDRSMN1; SMN2NPSR1PDK1HTT | |
| SCHEMBL201743 | 0.79 | EPHX1 (0.63) | TDP1POLBL3MBTL1RXFP1KDR | |
| SCHEMBL13199797 | 0.77 | LMNA (0.57) | KDREPHX1ARMAPTLMNA | |
| SCHEMBL13199794 | 0.77 | LMNA (0.57) | KDREPHX1ARMAPTLMNA | |
| SCHEMBL2704052 | 0.77 | LMNA (0.57) | KDREPHX1ARMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309603-B2 | SARMs and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-8080682-B2 | Substituted acylanilides and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-20100249228-A1 | SARMS AND METHOD OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2010-09-30 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7772433-B2 | SARMS and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7645898-B2 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | disclosed |
| US-20080076829-A1 | Substituted acylanilides and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| US-20080057068-A1 | SARMS and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-06 | — | — | US | disclosed |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-26 | — | — | US | disclosed |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-12 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-7186854-B2 | Process for making bicalutamide and intermediates thereof | SYNTHON IP INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | TDP1 3175/4885POLB 2764/4885L3MBTL1 1606/4885 |
| US-20080076829-A1 | Substituted acylanilides and methods of use thereof | CPT1B, MTPN, MUSK | TDP1 2258/4885POLB 2247/4885L3MBTL1 88/4885 |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | TDP1 4079/4885POLB 3475/4885L3MBTL1 4796/4885 |
| US-20080057068-A1 | SARMS and method of use thereof | SARM1, CKMT1A; CKMT1B, TNNI3 | TDP1 3216/4885POLB 3429/4885L3MBTL1 385/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | TDP1 3175/4885POLB 2764/4885L3MBTL1 1606/4885 |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | AR, ESRRA, SHBG | TDP1 3500/4885POLB 3203/4885L3MBTL1 1200/4885 |
| US-20100249228-A1 | SARMS AND METHOD OF USE THEREOF | CPT1B, FABP4, SARM1 | TDP1 3415/4885POLB 2778/4885L3MBTL1 1442/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | TDP1 4079/4885POLB 3475/4885L3MBTL1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.